• Corcept: Chief Development Officer William Guyer exercised options for 20,000 common shares at USD 21.65 on July 7, 2026.
• Guyer sold 20,000 common shares the same day for about USD 93.13 to USD 93.54 per share.
• Directly owned common shares fell to 3,985 following the transactions.
• Directly held stock options rose to 130,000, exercisable through Sept. 1, 2031.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Corcept Therapeutics Incorporated published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-298865), on July 08, 2026, and is solely responsible for the information contained therein.